ICIs for EBC

CE / CME

Immune Checkpoint Inhibitor Therapy for HER2-Negative Early-Stage Breast Cancer

Physician Assistants/Physician Associates: 0.50 AAPA Category 1 CME credit

Nurses: 0.50 Nursing contact hour

Pharmacists: 0.50 contact hour (0.05 CEUs)

Physicians: maximum of 0.50 AMA PRA Category 1 Credit

Released: May 13, 2024

Expiration: May 12, 2025

Tanya Gupta
Tanya Gupta, MD

Activity

Progress
1 2
Course Completed

References

  1. Lin YY, Gao HF, Yang X, et al. Neoadjuvant therapy in triple-negative breast cancer: a systematic review and network meta-analysis. Breast. 2022;66:126-135.
  2. Masuda N, Lee SJ, Ohtani S, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med. 2017;376:2147-2159.
  3. Geyer CE Jr, Garber JE, Gelber RD, et al. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer. Ann Oncol. 2022;33:1250-1268.
  4. Schmid P, Cortes J, Dent R, et al. Event-free survival with pembrolizumab in early triple-negative breast cancer. N Engl J Med. 2022;386:556-567.
  5. Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020;382:810-821.
  6. Schmid P, Cortés J, Dent RA, et al. Pembrolizumab or placebo plus chemotherapy followed by pembrolizumab or placebo for early-stage TNBC: updated EFS results from the phase III KEYNOTE-522 study. Presented at: European Society for Medical Oncology Congress 2023; October 20-24, 2023. Abstract LBA18.
  7. Schmid P, Cortés J, Dent RA, et al. KEYNOTE-522: phase III study of neoadjuvant pembrolizumab + chemotherapy vs. placebo + chemotherapy, followed by adjuvant pembrolizumab vs. placebo for early-stage TNBC. Presented at: 2021 European Society for Medical Oncology Virtual Plenary; September 16-21, 2021. Abstract VP7-2021.
  8. Pembrolizumab [prescribing information]. Rahway, NJ: Merck Sharp & Dohme; 2024. 
  9. Sharma P, Stecklein SR, Yoder R, et al. Clinical and biomarker findings of neoadjuvant pembrolizumab and carboplatin plus docetaxel in triple-negative breast cancer: NeoPACT phase 2 clinical trial. JAMA Oncol. 2024;10:227-235.
  10. Cardoso F, McArthur HL, Schmid P, et al. KEYNOTE-756: phase III study of neoadjuvant pembrolizumab (pembro) or placebo (pbo) + chemotherapy (chemo), followed by adjuvant pembro or pbo + endocrine therapy (ET) for early-stage high-risk ER+/HER2– breast cancer. Presented at: European Society for Medical Oncology Congress 2023; October 20-24, 2023. Abstract LBA21.
  11. Loi S, Curigliano G, Salgado RF, et al. A randomized, double-blind trial of nivolumab (NIVO) vs placebo (PBO) with neoadjuvant chemotherapy (NACT) followed by adjuvant endocrine therapy (ET) ± NIVO in patients (pts) with high-risk, ER+ HER2– primary breast cancer (BC). Presented at: European Society for Medical Oncology Congress 2023; October 20-24, 2023. Abstract LBA20.
  12. Yin Q, Wu L, Han L, et al. Immune-related adverse events of immune checkpoint inhibitors: a review. Front Immunol. 2023;14:1167975.
  13. Martins F, Sofiya L, Sykiotis GP, et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol. 2019;16:563-580.
  14. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: management of immunotherapy-related toxicities. v.1.2024. nccn.org. Accessed May 9, 2024.
  15. Schneider BJ, Naidoo J, Santomasso BD, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol. 2021;39:4073-4126.
  16. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: breast cancer. v.2.2024. nccn.org. Accessed May 9, 2024.
  17. Cortes J, Rugo HS, Cescon DW, et al. Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer. N Engl J Med. 2022;387:217-226.